Gilead’s former CCO to chair Memo board

Memo Therapeutics, a privately-held Swiss biotech company translating unique immune responses into superior medicines to treat viral infections and cancer, has announced the appointment of Paul Carter as chair of the board of directors.

Mr Carter has had a long executive career in the biopharma space, with commercial and M&A expertise spanning North America, Europe, and Asia. 

He has more than 10 years of experience working in the virology field at US biotech major Gilead Sciences (Nasdaq: GILD), most recently as executive vice president (EVP) and chief commercial officer, where he oversaw more than $30 billion dollars of sales and contributed to multiple M&A transactions.